Predictive parameters for imatinib failure in patients with chronic myeloid leukemia

References

• Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619–1630. doi: 10.1182/blood-2008-03-144790
   PubMed Web of Science ®Google Scholar
• Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–3127. doi: 10.1002/cncr.26679
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. doi: 10.1056/NEJMoa022457
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. doi: 10.1182/blood-2013-05-501569
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Abaza Y, Jabbour E. Selecting the best frontline treatment in chronic myeloid leukemia. Curr Hematol Malig Rep. 2015;10(2):145–157. doi: 10.1007/s11899-015-0254-5
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789–799.
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850–858. doi: 10.1093/jnci/90.11.850
   PubMedGoogle Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;21;118(3):686–692. doi: 10.1182/blood-2010-12-319038
   Web of Science ®Google Scholar
• Yamamoto E, Fujisawa S, Hagihara M, et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105(1):105–109. doi: 10.1111/cas.12321
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Nazha A, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012;119(19):4524–4526. doi: 10.1182/blood-2011-10-388967
   PubMed Web of Science ®Google Scholar
• Eliasson L, Clifford S, Barber N, et al. Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626–630. doi: 10.1016/j.leukres.2010.10.017
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120(7):1390–1397. doi: 10.1182/blood-2012-03-378919
   PubMed Web of Science ®Google Scholar
• Deininger M. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH 2009; Abstract 1126. 2009.
   Google Scholar
• Piccirillo JF, Costas I, Claybour P, et al. The measurement of comorbidity by cancer registries. J Registry Manag. 2003;30:8–14.
   Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. doi: 10.1182/blood-2005-05-2004
   PubMed Web of Science ®Google Scholar
• Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. J Am Geriatr Soc. 1968;16:622–626. doi: 10.1111/j.1532-5415.1968.tb02103.x
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336–1343. doi: 10.1038/leu.2015.73
   PubMed Web of Science ®Google Scholar
• Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood. 1982;60(6):1298–1304.
   PubMed Web of Science ®Google Scholar
• Chiu SC, Liu HH, Chen CL, et al. Extramedullary hematopoiesis (EMH) in laboratory animals: offering an insight into stem cell research. Cell Transplant. 2015;24(3):349–366. doi: 10.3727/096368915X686850
   PubMed Web of Science ®Google Scholar
• Baccarani M, Zaccaria A, Bagnara GP, et al. The relevance of extramedullary hemopoiesis to the staging of chronic myeloid leukemia. Boll Ist Sieroter Milan. 1978;57(3):257–270.
   PubMedGoogle Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56. doi: 10.1038/leu.2015.261
   PubMed Web of Science ®Google Scholar
• Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10):3794–3800. doi: 10.1182/blood-2002-09-2790
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Apperley JF, Gerrard G, Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood. 2012;119(8):1838–1843. doi: 10.1182/blood-2011-10-383000
   PubMed Web of Science ®Google Scholar
• Lee SE, Choi SY, Bang JH, et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet. 2012;205(11):563–571. doi: 10.1016/j.cancergen.2012.09.003
   PubMed Web of Science ®Google Scholar
• Schoch C, Haferlach T, Kern W, et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia. 2003;17(2):461–463. doi: 10.1038/sj.leu.2402813
   PubMed Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Palandri F, et al. Gruppo Italiano Malattie Ematologiche dell’Adulto CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood. 2011;117(21):5591–5599. doi: 10.1182/blood-2010-12-324228
   PubMed Web of Science ®Google Scholar
• Francis J, Dubashi B, Sundaram R, et al. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib. Med Oncol. 2015;32(8):213. doi: 10.1007/s12032-015-0665-0
   PubMed Web of Science ®Google Scholar